Quote:

---

it would be nice to screen for mutations before hand and afterwards to see what if any mutations emerged. I highly doubt that will be part of the trial design

---

They will almost certainly track viral load just to make sure the FDA is happy and prove that leronlimab has no negative effect on it. It will be interesting to see if they exclude CXCR4 carriers just to get cleaner results. If they do then they will certainly see if CXCR4 develops although that hasn't been the case in past trials.